Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Racial differences in microRNA and gene expression in hypertensive women.

Dluzen DF, Noren Hooten N, Zhang Y, Kim Y, Glover FE, Tajuddin SM, Jacob KD, Zonderman AB, Evans MK.

Sci Rep. 2016 Oct 25;6:35815. doi: 10.1038/srep35815.

2.

Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.

Vilela-Martin JF.

Drug Des Devel Ther. 2016 May 9;10:1627-39. doi: 10.2147/DDDT.S84782. Review.

3.

Angiotensin II-mediated hypertension impairs nitric oxide-induced NKCC2 inhibition in thick ascending limbs.

Ramseyer VD, Ortiz PA, Carretero OA, Garvin JL.

Am J Physiol Renal Physiol. 2016 Feb 17:ajprenal.00473.2015. doi: 10.1152/ajprenal.00473.2015. [Epub ahead of print]

PMID:
26887831
4.

Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertension.

Stegbauer J, Friedrich S, Potthoff SA, Broekmans K, Cortese-Krott MM, Quack I, Rump LC, Koesling D, Mergia E.

PLoS One. 2013 Nov 15;8(11):e80674. doi: 10.1371/journal.pone.0080674.

5.

Chronic vasodilation increases renal medullary PDE5A and α-ENaC through independent renin-angiotensin-aldosterone system pathways.

West CA, Shaw S, Sasser JM, Fekete A, Alexander T, Cunningham MW Jr, Masilamani SM, Baylis C.

Am J Physiol Regul Integr Comp Physiol. 2013 Nov 15;305(10):R1133-40. doi: 10.1152/ajpregu.00003.2013.

6.

Understanding the mechanisms of proteinuria: therapeutic implications.

Toblli JE, Bevione P, Di Gennaro F, Madalena L, Cao G, Angerosa M.

Int J Nephrol. 2012;2012:546039. doi: 10.1155/2012/546039.

7.
8.

Regulation of endothelial barrier function by cyclic nucleotides: the role of phosphodiesterases.

Surapisitchat J, Beavo JA.

Handb Exp Pharmacol. 2011;(204):193-210. doi: 10.1007/978-3-642-17969-3_8. Review.

9.

Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1.

Giachini FR, Lima VV, Carneiro FS, Tostes RC, Webb RC.

Hypertension. 2011 Mar;57(3):655-63. doi: 10.1161/HYPERTENSIONAHA.110.164327.

10.

Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II.

Mokni W, Keravis T, Etienne-Selloum N, Walter A, Kane MO, Schini-Kerth VB, Lugnier C.

PLoS One. 2010 Dec 3;5(12):e14227. doi: 10.1371/journal.pone.0014227.

11.

The PDE1A-PKCalpha signaling pathway is involved in the upregulation of alpha-smooth muscle actin by TGF-beta1 in adventitial fibroblasts.

Zhou HY, Chen WD, Zhu DL, Wu LY, Zhang J, Han WQ, Li JD, Yan C, Gao PJ.

J Vasc Res. 2010;47(1):9-15. doi: 10.1159/000231716.

13.

Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.

Vasan RS, Larson MG, Aragam J, Wang TJ, Mitchell GF, Kathiresan S, Newton-Cheh C, Vita JA, Keyes MJ, O'Donnell CJ, Levy D, Benjamin EJ.

BMC Med Genet. 2007 Sep 19;8 Suppl 1:S2.

15.

Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival.

Nagel DJ, Aizawa T, Jeon KI, Liu W, Mohan A, Wei H, Miano JM, Florio VA, Gao P, Korshunov VA, Berk BC, Yan C.

Circ Res. 2006 Mar 31;98(6):777-84.

Items per page

Supplemental Content

Support Center